1 Oversold Stock Ready to Bounce Back and 2 We Find Risky Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a co...
Pfizer Just Scored a Win That Wall Street Can't Ignore The pharmaceutical giant just extended the lifespan of one of its top drugs.
Pfizer Says Cancer Therapy Beats Standard Therapy In Late-Stage Blood Cancer Study Pfizer reports Phase 3 data showing ELREXFIO improved progression-free survival versus standard therapy in multiple myeloma study.
Do Wall Street Analysts Like Bristol-Myers Squibb Stock? Although Bristol-Myers Squibb has lagged behind the SPX over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.
Should You Buy, Sell, or Hold Pfizer at $27? The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question mark.
Are Wall Street Analysts Bullish on Pfizer Stock? Pfizer has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.
VCIT vs. IEI Comes Down to What Job Your Bond Sleeve Is Doing Explore how differences in bond type, risk, and income potential set these two popular ETFs apart for investors.
Is Pfizer's 6% Dividend Yield Safe? Here's What Investors Need to Know. Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.
Unusual Put Activity Is Flagging a Smart Trade Setup in This New Quantum Computing Stock Quantum computing firm Infleqtion led Thursday with a 133.59 Vol/OI ratio. The Jan. 15/2027 $10 put made up 23% of volume, which was 2.8 times its 30-day average, making the trade sneaky smart. Here’s why.
Wall Street Says Buy Merck Over Pfizer. The Numbers Tell a More Complicated Story. A tougher market puts two healthcare dividend giants in focus, as investors weigh income, stability, valuation, and long-term upside.
Should You Forget Pfizer and Buy This Pharma Stock Instead? Pfizer's shares have rebounded, but is AbbVie still a better buy among pharmaceutical stocks?
Why Merck (MRK) Shares Are Trading Lower Today What Happened? Shares of global pharmaceutical company Merck (
NYSE:MRK ) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a...
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.
This Drug Stock Has Crushed the S&P 500 Over the Last Decade Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock.
Where Will Pfizer Stock Be in 3 Years? The healthcare giant has been investing heavily in its future growth.
Better Long-Term Buy: Eli Lilly or Viking Therapeutics? One is a behemoth, the other is a minnow, but both have promising opportunities in the GLP-1 space.
2 Value Stocks to Research Further and 1 Facing Headwinds Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...
QSM Asset Management Loads Up 611,000 Mobileye Shares Mobileye develops advanced driver assistance and autonomous driving technologies for global automotive manufacturers and suppliers.
